Find participating medical centers and current study status in each of them
Find participating medical centers
-
Home
-
Clinical Study Finder
- LIBERTO
A clinical extension trial to look at how well and safe ocrelizumab works long-term in people with multiple sclerosis who benefitted from ocrelizumab in a previous F. Hoffmann-La Roche Ltd sponsored trial
This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)
Autoimmune Disorder Multiple Sclerosis (MS)
- Results
-
Download -
Study results
LPS MN39158 LIBERTO Final Results November 2022 English
(PDF, 2.1 MB)
LPS MN39158 LIBERTO Final Results November 2022 Czech
(PDF, 0.5 MB)
LPS MN39158 LIBERTO Final Results November 2022 Danish
(PDF, 0.2 MB)
LPS MN39158 LIBERTO Final Results November 2022 Dutch Netherlands
(PDF, 0.7 MB)
LPS MN39158 LIBERTO Final Results November 2022 Estonian
(PDF, 0.5 MB)
LPS MN39158 LIBERTO Final Results November 2022 Finnish
(PDF, 0.2 MB)
LPS MN39158 LIBERTO Final Results November 2022 French
(PDF, 0.7 MB)
LPS MN39158 LIBERTO Final Results November 2022 Italian
(PDF, 0.4 MB)
LPS MN39158 LIBERTO Final Results November 2022 Norwegian
(PDF, 0.5 MB)
LPS MN39158 LIBERTO Final Results November 2022 Russian
(PDF, 0.5 MB)
LPS MN39158 LIBERTO Final Results November 2022 Spanish
(PDF, 0.3 MB)
LPS MN39158 LIBERTO Final Results November 2022 Swedish
(PDF, 0.8 MB)
Explore related studies
For the latest version of this information please go to www.forpatients.roche.com